Investors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders bought 23,699 call options on the company. This is an increase of approximately 51% compared to the average daily volume of 15,658 call options.

Analyst Ratings Changes

A number of analysts have recently issued reports on RXRX shares. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock traded up $0.16 during mid-day trading on Monday, hitting $7.65. The company had a trading volume of 26,130,139 shares, compared to its average volume of 19,527,773. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock's 50 day moving average price is $7.15 and its 200-day moving average price is $6.89. Recursion Pharmaceuticals has a 52-week low of $5.60 and a 52-week high of $15.74. The company has a market capitalization of $2.99 billion, a P/E ratio of -5.00 and a beta of 0.86.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now owns 7,066,113 shares of the company's stock, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals in the third quarter worth about $25,000. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $27,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.